Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CC 90011

Drug Profile

CC 90011

Alternative Names: CC-90011

Latest Information Update: 31 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Quanticel Pharmaceuticals
  • Developer Celgene Corporation
  • Class Antineoplastics
  • Mechanism of Action Lysine specific demethylase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-small cell lung cancer; Small cell lung cancer
  • Phase I Non-Hodgkin's lymphoma; Prostate cancer; Solid tumours

Most Recent Events

  • 16 Jul 2021 Phase-I clinical trials in Prostate cancer (Combination therapy, Metastatic disease, Second-line therapy or greater, Hormone refractory) in USA (PO) (NCT04628988)
  • 28 Feb 2021 Updated efficacy, adverse events and pharmacodynamic data from a phase I trial in Solid tumours presented at the 19th International Congress on Targeted Anticancer Therapies (TAT-2021)
  • 10 Feb 2021 Celgene plans a phase I/II trial for Acute myeloid leukaemia (Combination therapy, Second line therapy or greater, First-line therapy ) in the US in May 2021 (NCT04748848)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top